phosphorus-radioisotopes and Sarcoma

The application of 31P MR spectroscopy in the characterization and treatment of malignant human extremity tumors is reviewed and placed in the perspective of results obtained in murine sarcomas. Despite the now widespread acquisition of gradient localized spectral maps, the low spatial resolution that can be achieved at 1.5 or 2 T with 31P MRS, greatly limits its use in the study of tumor heterogeneity. The potential of 31P MRS is in the evaluation and monitoring of large inoperable extremity tumors. There are early spectral changes in human extremity sarcomas monitored after therapy, and recent studies have shown that the 31P MR spectra measured before treatment, and the changes in phosphate metabolites measured shortly thereafter, correlate with the clinical response after 2 or 3 months. Larger clinical studies are needed to confirm whether correlations of, for instance, pretreatment tumor pH with necrosis at resection and Pi decrease with tumor regression, can be used as a predictive test for clinical response.

Topics: Animals; Antineoplastic Agents; Cytokines; Extremities; Humans; Magnetic Resonance Spectroscopy; Mice; Phosphorus Radioisotopes; Radiotherapy; Sarcoma; Sarcoma, Experimental

Children with pulmonary sarcomas who have diffuse contamination of the pleural cavity present a difficult management problem for the radiation oncologist. Doses required to control even microscopic disease exceed lung tolerance. We report on the use of intracavity colloid P-32 in an attempt to treat the pleural surface and spare normal lung parenchyma and tissues of the chest wall. Three children--18 months, 12 years, and 3 years of age--had spillage of pulmonary sarcomas into the chest cavity. All children were treated with systemic chemotherapy. Initially, 0.5 mCi of technetium sulfur colloid (99mTc-sulfur colloid) was instilled into the pleural space to ascertain even distribution of isotope. This was then followed by installation of 5.0 mCi of colloidal P-32. Uniform distribution was then confirmed by bremsstrahlung scanning. All three patients are in complete remission 3.5 years, 3 years, and 1 year after treatment, respectively. The major toxicity was asymptomatic pleural thickening, which could be confused with disease. This was confirmed histologically to be fibrous in the first patient. The process diminished or stabilized with time in all 3 patients over the period of observation. In this small series, intrapleural colloidal P-32 appeared to be safe and well tolerated and would be expected to be less toxic than wide-field external beam in the treatment of spilled pulmonary sarcomas.

Topics: Child; Child, Preschool; Colloids; Humans; Infant; Injections, Intralesional; Lung Neoplasms; Male; Phosphorus Radioisotopes; Pleural Neoplasms; Radionuclide Imaging; Radiopharmaceuticals; Remission Induction; Respiratory Function Tests; Sarcoma

The oncogenic power of 32P was demonstrated in salivary glands. An intraglandular injection of 0.25 mCi of chromic colloidal phosphate (32P) was administered to young adult Wistar rats. Seven months post-injection, tumors began to appear in the neck region in 64% of the rats. The tumors were sarcomas (50%), carcinomas (35.70%), and carcino-sarcomas (14.28%).

Topics: Animals; Carcinoma; Male; Neoplasms, Experimental; Neoplasms, Radiation-Induced; Phosphorus Radioisotopes; Rats; Rats, Inbred Strains; Salivary Gland Neoplasms; Sarcoma

Topics: Animals; Circadian Rhythm; Lymphoma, Non-Hodgkin; Neoplasm Transplantation; Neoplasms, Experimental; Phosphorus; Phosphorus Radioisotopes; Rats; Sarcoma

Cancer of the ovary is the leading cause of death from gynecologic cancer. The constant challenge presented by ovarian cancer is that about 11,000 women die from ovarian cancer each year and the results in 1974 are no better than have been achieved in the previous two decades. Standard practice of treatment for truly invasive common epithelial ovarian cancer includes total hysterectomy, bilateral salpingo-oophorectomy, appendectomy, omentectomy, and post-surgical insertion of tubes and administration of P32 (if the disease is of limited extent). Although it is occasionally necessary to resect isolated segments of bowel, exenterative or ultraradical surgery in the management of ovarian cancer is not usually chosen because of the natural history of the disease. However, aggressive surgery is indicated not so much because it is curative, but because it potentiates other forms of treatment. All stages I through IV are treated surgically, to remove as much tumor as possible without running a risk of a gastrointestinal or genitourinary fistula. Radiation therapy has been utilized in addition to the surgical therapy in stage IV to control supraclavicular and/or inguinal node involvement. Single agent alkylating chemotherapy is chosen for the treatment of common epithelial ovarian cancers. Combination chemotherapy does not produce better results at this time, except in the treatment of embryonal tumors. The treatment of the common epithelial tumors by stage is outlined. The treatment of germ cell tumors, gonadal stromal tumors, ovarian tumors in childhood, ovarian tumors in pregnancy, as well as tumors not specific for the ovary, will also be discussed.

Topics: Adolescent; Adult; Alkylating Agents; Appendectomy; Castration; Child; Dysgerminoma; Female; Granulosa Cell Tumor; Humans; Hysterectomy; Lymphatic Metastasis; Neoplasm Metastasis; Neoplasms, Gonadal Tissue; Omentum; Ovarian Neoplasms; Pelvic Exenteration; Phosphorus Radioisotopes; Pregnancy; Pregnancy Complications; Radiotherapy; Sarcoma; Sertoli Cell Tumor; Teratoma

Topics: Alkaline Phosphatase; Animals; Centrifugation, Density Gradient; Electrophoresis, Polyacrylamide Gel; Evaluation Studies as Topic; Female; Hydrogen-Ion Concentration; Kinetics; Methods; Mice; Molecular Weight; Osmolar Concentration; Phosphoproteins; Phosphorus Radioisotopes; Pronase; Protein Kinases; Rabbits; Reticulocytes; Ribosomes; Sarcoma; Spectrophotometry, Ultraviolet; Streptomyces griseus; Time Factors

Topics: Bone and Bones; Bone Neoplasms; Humans; Joints; Neoplasms; Phosphorus; Phosphorus Radioisotopes; Sarcoma

Topics: Gold Radioisotopes; Neoplasm Transplantation; Neoplasms; Phosphorus; Phosphorus Radioisotopes; Radioactivity; Radioisotopes; Sarcoma; Transplantation, Heterologous

Topics: Animals; Humans; Neoplasms; Phosphorus; Phosphorus Radioisotopes; Rats; Sarcoma; Sarcoma, Experimental

Topics: Animals; Bone Neoplasms; Mice; Neoplasms; Neoplasms, Experimental; Osteosarcoma; Phosphorus; Phosphorus Radioisotopes; Sarcoma